We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 542

Amgen and Apotex do the biosimilar patent dance
  • Foley & Lardner LLP
  • USA
  • August 27 2015

Amgen has filed a complaint under the Biologics Price Competition and Innovation Act (BPCIA), asserting that a biosimilar application filed by Apotex


Kyle Bass loses round 1 of IPR attack against pharmabiotech patents
  • Foley & Lardner LLP
  • USA
  • August 26 2015

On August 24, 2015, the Patent Trial and Appeal Board (PTAB) declined institution of two petitions filed by Coalition For Affordable Drugs for Inter


What is the latest on amendments in PTAB proceedings?
  • Foley & Lardner LLP
  • USA
  • August 25 2015

The conference addressed the very recent Federal Circuit decision in Microsoft v. Proxyconn, in which the court affirmed the PTAB’s restrictive


Delaware judges are finding patent claims indefinite post-Nautilus
  • Foley & Lardner LLP
  • USA
  • August 24 2015

It has been a little more than a year since the Supreme Court rendered its decision in Nautilus, lowering the standard for finding patent claim terms


Protecting diagnostic innovation two actor infringement liability
  • Foley & Lardner LLP
  • USA
  • August 24 2015

In Akamai Techs. Inc. v. Limelight Networks, Inc., (August 13, 2015 Fed. Cir.) an en banc Federal Circuit unanimously held that direct infringement


A royalty by any other name: post-expiration payments after Kimble v. Marvel
  • Foley & Lardner LLP
  • USA
  • August 21 2015

Patent holders and accused infringers will need to continue being creative in drafting license agreements after the Supreme Court's recent decision


Federal Circuit expands direct divided infringement
  • Foley & Lardner LLP
  • USA
  • August 20 2015

In an en banc, per curiam decision in Akamai Technologies, Inc. v. Limelight Networks, Inc., on remand from the Supreme Court, the Federal Circuit


Sequenom seeks rehearing en banc
  • Foley & Lardner LLP
  • USA
  • August 18 2015

Sequenom, Inc. has filed a petition for rehearing en banc of the Federal Circuit decision that held its diagnostic method claims invalid under 35 USC


Lessons learned from the 1st successful pharmaceutical IPR defense of Orange Book listed patents
  • Foley & Lardner LLP
  • USA
  • August 18 2015

In three petitions filed on the same day in 2013, styled Amneal v. Supernus, Amneal filed what appears to be the first challenge of Orange Book


The value of prophetic examples
  • Foley & Lardner LLP
  • USA
  • August 13 2015

In Allergan, Inc. v. Sandoz, Inc., the Federal Circuit affirmed the district court decision that upheld the validity of the Allergan patents relating